See more : Spirax-Sarco Engineering plc (SPXSF) Income Statement Analysis – Financial Results
Complete financial analysis of Axonics, Inc. (AXNX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Axonics, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Ohio Valley Banc Corp. (OVBC) Income Statement Analysis – Financial Results
- Powerstorm Holdings, Inc. (PSTO) Income Statement Analysis – Financial Results
- Odonate Therapeutics, Inc. (ODTC) Income Statement Analysis – Financial Results
- Hang Lung Group Limited (0010.HK) Income Statement Analysis – Financial Results
- Galeo Concept SA (MLGAL.PA) Income Statement Analysis – Financial Results
Axonics, Inc. (AXNX)
About Axonics, Inc.
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 366.38M | 273.70M | 180.29M | 111.54M | 13.82M | 707.00K | 128.12K | 0.00 |
| Cost of Revenue | 91.83M | 76.04M | 64.57M | 44.44M | 6.49M | 356.00K | 117.94K | 625.12K |
| Gross Profit | 274.55M | 197.67M | 115.72M | 67.09M | 7.33M | 351.00K | 10.17K | -625.12K |
| Gross Profit Ratio | 74.94% | 72.22% | 64.18% | 60.15% | 53.04% | 49.65% | 7.94% | 0.00% |
| Research & Development | 34.89M | 34.41M | 37.30M | 29.17M | 20.18M | 19.40M | 12.33M | 12.51M |
| General & Administrative | 45.75M | 40.24M | 32.79M | 25.55M | 19.08M | 9.36M | 4.82M | 4.46M |
| Selling & Marketing | 189.56M | 156.02M | 105.79M | 66.13M | 48.67M | 3.72M | 1.03M | 516.08K |
| SG&A | 235.32M | 196.26M | 138.57M | 91.68M | 67.75M | 13.09M | 5.85M | 4.97M |
| Other Expenses | 14.96M | 9.38M | 7.24M | -412.15K | 0.00 | 0.00 | -20.82K | -291.00 |
| Operating Expenses | 270.20M | 240.05M | 183.11M | 120.85M | 87.93M | 32.49M | 18.19M | 17.48M |
| Cost & Expenses | 392.44M | 316.09M | 247.68M | 165.30M | 94.42M | 32.84M | 18.30M | 17.48M |
| Interest Income | 17.31M | 5.13M | 40.00K | 761.00K | 2.97M | 998.00K | 200.58K | 84.02K |
| Interest Expense | 0.00 | 2.43M | 7.43M | 1.87M | 2.31M | 1.34M | 22.00K | 0.00 |
| Depreciation & Amortization | 12.49M | 12.72M | 10.13M | 2.64M | 1.59M | 946.00K | 725.39K | 625.12K |
| EBITDA | 7.78M | -47.16M | -61.73M | -51.30M | -78.03M | -31.19M | -17.33M | -16.77M |
| EBITDA Ratio | 2.12% | -10.18% | -33.34% | -47.52% | -561.69% | -4,404.38% | -13,479.81% | 0.00% |
| Operating Income | -26.06M | -42.39M | -67.39M | -53.76M | -80.60M | -32.14M | -18.17M | -17.48M |
| Operating Income Ratio | -7.11% | -15.49% | -37.38% | -48.20% | -583.21% | -4,545.54% | -14,185.62% | 0.00% |
| Total Other Income/Expenses | 17.31M | 2.63M | -7.48M | -1.15M | 665.00K | -345.00K | 114.33K | 82.93K |
| Income Before Tax | -8.74M | -62.32M | -79.29M | -54.91M | -79.93M | -32.48M | -18.06M | -17.40M |
| Income Before Tax Ratio | -2.39% | -22.77% | -43.98% | -49.23% | -578.39% | -4,594.34% | -14,097.05% | 0.00% |
| Income Tax Expense | -2.66M | -2.62M | 782.00K | 1.00K | 1.00K | 1.00K | -20.82K | -291.00 |
| Net Income | -6.09M | -59.70M | -80.07M | -54.92M | -79.94M | -32.48M | -18.06M | -17.40M |
| Net Income Ratio | -1.66% | -21.81% | -44.41% | -49.24% | -578.40% | -4,594.48% | -14,097.05% | 0.00% |
| EPS | -0.12 | -1.28 | -1.86 | -1.48 | -2.80 | -4.64 | -0.97 | -0.95 |
| EPS Diluted | -0.12 | -1.28 | -1.86 | -1.48 | -2.80 | -4.64 | -0.97 | -0.95 |
| Weighted Avg Shares Out | 49.08M | 46.68M | 43.07M | 36.98M | 28.57M | 7.00M | 18.62M | 18.38M |
| Weighted Avg Shares Out (Dil) | 49.08M | 46.68M | 43.07M | 36.98M | 28.57M | 7.00M | 18.62M | 18.38M |
Axonics Reports First Quarter 2024 Financial Results
Boston Scientific Announces Results for First Quarter 2024
FTC seeks more information on Boston Scientific's $3.7 bln Axonics deal
All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy
Axonics Stockholders Approve Merger Agreement with Boston Scientific
Axonics Provides Update on Inter Partes Review Proceedings
Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System
Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
Axonics Responds to ITC Action by Medtronic
Axonics Modulation Technologies (AXNX) Q4 Earnings and Revenues Surpass Estimates
Source: https://incomestatements.info
Category: Stock Reports